Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CRESCITA THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 0.4 CAD | 0.00% | +3.90% | -39.39% | |
| Sales 2022 | 23.52M 17.34M | Sales 2023 * | - | Capitalization | 13.49M 9.95M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 * | - | EV / Sales 2022 | 0,29x |
| Net cash position 2022 | 6.7M 4.94M | Net cash position 2023 * | - 0 | EV / Sales 2023 * | - |
| P/E ratio 2022 | 16,5x | P/E ratio 2023 * | Employees | - | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 89.95% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -1.23% | ||
| 1 month | -34.43% | ||
| 3 months | -41.18% | ||
| 6 months | -38.46% | ||
| Current year | -39.39% |
1 week
0.40
0.40
1 month
0.380.61
Current year
0.380.79
1 year
0.380.79
3 years
0.381.01
5 years
0.381.23
10 years
0.351.99
| Managers | Title | Age | Since |
|---|---|---|---|
Serge Verreault
CEO | Chief Executive Officer | - | - |
Jose DaRocha
DFI | Director of Finance/CFO | - | 2017 |
Daniel Chicoine
CHM | Chairman | 69 | 2016 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 2016 | |
Daniel Chicoine
CHM | Chairman | 69 | 2016 |
David Copeland
BRD | Director/Board Member | - | 2016 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-05 | 0.4 | 0.00% | 1 000 |
| 23-12-04 | 0.4 | 0.00% | 1,000 |
| 23-12-01 | 0.4 | 0.00% | 500 |
| 23-11-30 | 0.4 | +3.90% | 597 |
| 23-11-28 | 0.385 | -4.94% | 225,800 |
Delayed Quote Toronto Stock Exchange, December 04, 2023 at 03:54 pm EST
More quotes
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Companyâs contract development and manufacturing organization infrastructure, and sales of product development services.
Sector
Pharmaceuticals
Calendar
2024-03-19
- Q4 2023 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -39.39% | 6 M $ | |
| +60.09% | 527 B $ | |
| +46.91% | 448 B $ | |
| -10.06% | 382 B $ | |
| -5.31% | 266 B $ | |
| -10.80% | 255 B $ | |
| -13.77% | 227 B $ | |
| +2.06% | 203 B $ | |
| -9.56% | 201 B $ | |
| -42.86% | 165 B $ |
